All posts by imreal

GeBBS Named as “Leader” in Everest Group Medical Coding Operations PEAK Matrix® Assessment 2023


We are honored to be named as Leader in Everest Group’s PEAK Matrix

GeBBS Healthcare Solutions, Inc.(ChrysCapital portfolio company), a leading provider of Revenue Cycle Management (RCM) Solutions for Healthcare Providers and Payers, announced that it has been named as a Leader in Medical Coding Operations by Everest Group. GeBBS was recognized in the top quartile for performance in market success and capability advancement as part of Everest Group’s Medical Coding Operations PEAK Matrix® Assessment 2023.

The report evaluated 22 operations service providers based on market impact, vision, and the ability to deliver services successfully-as defined by subdimensions including market adoption, portfolio mix, value delivered, and strategic vision-to identify each organization’s overall market leadership position, labeled as Aspirant, Major Contender, or Leader. GeBBS has been named “Leader” for its significant growth and market success.

Medical coding is one of the most outsourced segments in the Revenue Cycle Management (RCM) value chain. GeBBS’ NLP powered iCode platform complimented with one of the largest pools of certified and highly trained coding experts in the industry focuses on enhanced accuracy, compliance, denial prevention, and accurate reimbursement to optimize performance with results driven outcomes.

“We are honored to be named as Leader in Everest Group’s PEAK Matrix,” said Milind Godbole, CEO & Managing Director of GeBBS Healthcare Solutions. “Our leadership position in this assessment validates our long-standing vision and market differentiation in exceeding client expectations while helping them achieve new levels of success.”

The Everest Group PEAK Matrix is a proprietary framework for assessing the relative market success and overall capability of service providers based on Performance, Experiences, Ability, and Knowledge. Each service provider is comparatively assessed in two dimensions: market success and delivery capabilities. Market success is measured by revenue, number of clients and year-over-year growth. Delivery capability is measured by the scale of operations, scope, technology and innovation, delivery footprint and buyer satisfaction. The resulting matrix categorizes service providers as Leaders, Major Contenders, and Aspirants.

About GeBBS

GeBBS Healthcare Solutions is a KLAS rated leading provider of Revenue Cycle Management (RCM) services and Risk Adjustment solutions. GeBBS’ innovative technology, combined with over 12000+ strong global workforce, helps clients improve financial performance, adhere to compliance, and enhance the patient experience. Headquartered in Los Angeles, CA, GeBBS has won numerous accolades for its medical coding outsourcing and medical billing outsourcing, including being ranked in Modern Healthcare’s Top 20 Largest RCM Firms, Black Book Market Research’s Top 20 RCM Outsourcing Services, and Inc. 5000’s fastest growing private companies in the U.S. For more information, please visit our website.

About Everest Group

Everest Group is a consulting and research firm focused on strategic IT, business services, engineering services, and sourcing. Our clients include leading global enterprises, service providers, and investors. Through our research-informed insights and deep experience, we guide clients in their journeys to achieve heightened operational and financial performance, accelerated value delivery, and high-impact business outcomes. Details and in-depth content are available at http://www.everestgrp.com/.

For more information contact:

Tyler Cowart

310-953-4444 ext. 214

tyler.cowart@gebbs.com

Share article on social media or email:

Study Leveraging DEARhealth Care Management Platform for Ovarian Cancer Care Launched


GSK is pleased to provide funding to support the UC Cancer Consortium, leveraging DEARhealth’s innovative technology, as part of our Patient Empowerment Alliance,” said Shannon Altimari, Global Head of Oncology Advocacy to Outcomes, GSK.

DEARhealth Inc., a health tech company focused on patients with a chronic condition and their continuous care management, announced today the launch of a randomized, multi-center, controlled study to assess the efficacy of DEARhealth’s risk-based care management platform in improving the health of women with ovarian cancer.

The study “Value-Based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)” will be led by the University of California (UC) Cancer Consortium, a collaboration of UC’s five National Cancer Institute-designated Comprehensive Cancer Centers. The study is part of the GSK supported studies program and the company’s Patient Empowerment Alliance (P.E.A.), an innovative program created to help test, measure, and validate tools that show potential to empower patients as core members of their oncology care team with the goal of improving care outcomes.

Gynecologic oncologists at each UC Cancer Center will direct the study, which follows a successful feasibility study at UCLA Jonsson Comprehensive Cancer Center, which was led by Joshua G. Cohen, MD, a gynecologic oncologist formerly at the David Geffen School of Medicine at UCLA. Dr. Tiffany Lai, Assistant Professor in gynecologic oncology at UCLA will serve as the Principal Investigator. Co-Principal Investigators at each UC Cancer Center includes Drs. Lee-May Chen (UCSF), Pratibha Binder (UCSD), Jill Tseng (UCI), Hui (Amy) Chen and Rebecca Brooks (UC Davis), and Cortney Eakin (UCLA).

“We’re excited to embark on this important study that we hope will show the benefits of a harmonized care pathway for ovarian cancer accessible through the DEARhealth care management platform,” said Dr. Daniel Hommes, MD, PhD, and Co-founder of DEARhealth.

“GSK is pleased to provide funding to support the UC Cancer Consortium, leveraging DEARhealth’s innovative technology, as part of our Patient Empowerment Alliance,” said Shannon Altimari, Global Head of Oncology Advocacy to Outcomes, GSK. “The P.E.A. is a novel component of our supported studies program that applies scientific rigor to the assessment of technologies, platforms, and interventions, which may have a positive impact on patient engagement and outcomes.”

DEARhealth’s care management platform offers risk-based care pathway recommendation functionality with the input of data from electronic medical record (EMR) systems, to support provider teams, patients, and their caregivers in the management of chronic conditions. Recommendations are focused on the Triple Aim: enhancing experiences, improving outcomes, and managing costs. The DEARhealth platform uses clinical data and continuously captured patient-reported outcome measures (PROMs), including those related to disease progression, medications, and mental health, to assess patients and deliver recommendations to adjust the treatment to new developments in a patient’s health status. The study aims to deliver evidence-based care recommendations to providers and patients in real-time.

Participants in the study will need to opt-in to data sharing from their UC electronic medical record as part of consent for the trial. All patient data will be securely encrypted for patient privacy.

###

About DEARhealth

DEARhealth is a health tech company founded in 2013, by senior University of California, Los Angeles (UCLA) medical experts to transform healthcare by using risk-based care pathways for chronic disease care management. DEARhealth is a validated, software as a medical device, whose partners include health systems, providers, payers, and pharmaceutical companies globally. Investors in DEARhealth include Philips Health Technology Ventures, Vesalius Biocapital III and Health Innovations. To learn more about DEARhealth visit http://www.dearhealth.com or contact info@dearhealth.com.

Share article on social media or email:

GTMRx Executive Director Katherine H. Capps to Speak at APG Colloquium on Role of Pharmacists in Team-Based Care


News Image

Capps, who leads the GTMRx coalition of over 1,700 members calling for medication management reform, is part of the panel discussion on how pharmacists, as medication specialists, can work in collaborative practice with physicians to ensure the safe, effective, and appropriate use of medications.

Today, The Get the Medications Right™ (GTMRx) Institute, the catalyst for change to medication management that brings together critical stakeholders across health care, is announcing that Executive Director and Co-Founder, Katherine H. Capps will be speaking at this year’s America’s Physician Groups Colloquium (APG). The panel, comprised of leaders in healthcare and pharmacy practice, will address the importance of including pharmacists in the team-based care approach.

APG, which represents more than 335 physician groups with approximately 170,000 physicians providing care to nearly 90 million patients, is hosting this year’s Colloquium in Washington, D.C., and aims to provide hands-on knowledge and best practices from physician groups with successful track records in value-based care delivery, along with the big-picture view from policymakers bringing change to the healthcare system. Capps, who leads the GTMRx coalition of over 1,700 members calling for medication management reform, is part of the panel discussion on how pharmacists, as medication specialists, can work in collaborative practice with physicians to ensure the safe, effective, and appropriate use of medications. The goal of this approach is to decrease physician burnout, increase patient satisfaction, and save lives.

WHAT: APG Colloquium 2022 Breakout Session, “How Pharmacists Elevate Team-Based Care”

  • Attendees will hear about the novel ways some physician organizations are incorporating pharmacists on their teams to optimize medication use, improve patient care, reduce the total cost of care, and impact patient and provider satisfaction. Decreasing physician workload, increasing patient satisfaction, more effectively managing chronic conditions, decreasing hospitalizations, and reducing waste are driving value in these team-based care models.

WHO: Panelists include:

  • Katherine Herring Capps, Co-Founder & Executive Director, GTMRx Institute
  • Jordan Haag, PharmD, Director, Ambulatory Pharmacy Practice, Mayo Clinic
  • Bahar Davidoff, MBA, PharmD, Vice President, Pharmacy, Heritage Provider Network
  • Esteban Gallardo, PharmD, Chief of Pharmacy, CareAllies

WHEN: Tuesday, November 1 from 3:00 pm – 4:15 pm ET

WHERE: Grand Hyatt, Washington, DC

  • 1000 H St NW
  • Washington, DC 20001

The GTMRx Institute advocates for the broad adoption of CMM, a more rational process of care in which physicians and clinical pharmacists work together to ensure that each medication is appropriate for the patient; very much in line with the aims and goals of APG Colloquium 2022. For more information on the APG Colloquium 2022, and to register for the event, click here.

About the Get the Medications Right™ Institute

The GTMRx Institute is a catalyst for change that brings critical stakeholders together, bound by the urgent need to get the medications right. We are physicians, pharmacists, nurses, patients, health IT innovators, drug and diagnostics companies, consumer groups, employers, and payers—aligned to save lives and save money through comprehensive medication management. By showcasing evidence and innovation, we motivate practice transformation and push payment and policy reform. Together, we ACT to champion the appropriate, effective, safe, and precise use of medication and gene therapies. Learn more at gtmr.org.

Share article on social media or email:

New Jeeva eClinical Research Technology Enables Global Diversity Inclusion and Multi-Center Collaboration


News Image

Empowering remote patient-researcher interactions through the use of human-centric digital technology enables us to deliver dramatic improvements in the diversity of study populations scalable to a variety of clinical trials with rapid configurations rather than building a custom app each time.

Diversity and inclusion in clinical trials are critical to achieving accurate and reliable results.(1) Participation in clinical trials is voluntary, and individuals of different ages, genders, races, ethnicities, genetic backgrounds, geographic locations, and environments will respond differently to the same treatments. An effective way to achieve diversity in clinical trials is through decentralization with standardized procedures across multiple sites.(2) To facilitate the efficient execution of multi-center clinical trials globally, Dr. Harsha Rajasimha, Founder and CEO of Jeeva Informatics, and his team have developed the modular Jeeva™ eClinical Cloud.

Researchers in the U.S. and abroad have selected the Jeeva eClinical Platform for their pivotal clinical trials. U.S.-based Frantz Viral Therapeutics (FVT), a joint venture of Georgetown University Medical Center and Frantz Medical Group, developed and clinically demonstrated safety and efficacy in three applications of an antiviral drug for the treatment of HPV-associated pre-invasive disease of the anogenital tract. FVT selected the Jeeva eClinical platform to effectively execute a multi-site phase 2 clinical trial focused on the treatment of anal squamous intraepithelial lesions (anal HSIL). “I appreciate the functionality of the system. The Jeeva team has been helpful in working with us to provide exactly what we needed for our pivotal study,” says Mihaela Plesa, Director of Clinical Operations at Frantz Viral Therapeutics.

ImmunoACT is pioneering the first cell and gene therapy in India for patients’ long-term cures, both for common and rare diseases. They chose Jeeva to accelerate clinical development timelines without tapping into a large, full-service Contract Research Organization (CRO) or creating an in-house IT infrastructure. ImmunoACT selected Jeeva as a strategic technology partner to optimize their clinical trial operations from the very early stage through study closeout and long-term follow-up. “We need to bring the healthcare costs and product development costs down, especially in the developing world. Clinical trial costs are a significant part of product development costs. We are confident that by partnering with Jeeva, we can find the right value for money proposition without compromising on the quality,” says Shirish Arya, Director of Strategy at ImmunoACT.

With regional deployments of the Jeeva eClinical Cloud and TRIALMAGNET, we are able to support local regulatory requirements for the physical storage of clinical trial data and make it affordable in emerging markets with local partners and expertise on the ground.

The company has established numerous partnerships with CROs, site networks, and investigators in the US, India, and Latin America. Jeeva recently strategically partnered with MetFlux Research Services Pvt. Ltd. (MetFlux) for virtual clinical trials and software distribution in India. “Our partnership with Jeeva brings the world’s first-of-its-kind clinical research service, combining MetFlux’s Investigative PhysiologyTM platform with Jeeva’s eClinical trials platform. The partnership enables end-to-end pre-clinical and clinical trial solutions to pharma and healthcare companies seamlessly linking deep physiology research, advanced research analytics with the scalable digital clinical trial execution, and outstanding customer support,” says Professor Venkatesh Kareenhalli, Founder and Director of MetFlux.

U.S.-based Koncord Clinical Research Services (KCRS) needed a mobile-friendly software platform for engaging diverse patients in the Texas-Mexico border region. With Jeeva eClinical Cloud, the team is gathering accurate and faster eConsent, followed by biospecimen collection from elderly Hispanic persons with liver and gastrointestinal disorders. “In looking for a software partner, our research coordinators and investigators in the field could call the Jeeva team anytime, get reliable support, and have reassurance as we enroll patients on the go. You can count on Jeeva when time is of the essence in operationalizing a clinical trial,” attests Dr. Emmanuel Gorospe, Chief Medical Officer of KCRS.

Farmacon Global, a strategic CRO based in the U.S. with an extensive reach to clinical research sites in Latin America and outreach ability to Latinos in the U.S., recently partnered with Jeeva eClinical Platform to enable the Hispanic and Latinx communities with rare diseases, opportunities to access therapies in clinical trials. “Having evaluated numerous clinical trial platforms, Jeeva was refreshing in its vision to engage underrepresented minorities, focus on rare diseases, and collaborative approach beyond technology. We are eager to enable patient education, recruitment, and retention in rare disease clinical studies, such as patient registries and cell/gene therapies,” says Sara Tylosky, CEO of Farmacon Global.

Based on his lived experiences of caring for young loved ones with rare and chronic conditions, Dr. Rajasimha is driven to help patients gain access to critical and life-saving therapies faster and with the least burden. He says, “Empowering remote patient-researcher interactions through the use of human-centric digital technology enables us to deliver dramatic improvements in the diversity of study populations scalable to a variety of clinical trials with rapid configurations rather than building a custom app each time.”

The globalization, decentralization, and diversification of clinical trials are just beginning, but the future is bright.

About Jeeva Informatics Solutions

The personal experience of losing a child born with a rare disease and a brother with a chronic disease became the springboard for Dr. Harsha Rajasimha to apply his years of postdoctoral training at NIH and FDA to accelerating therapies for rare and common conditions. He knew that technology in itself is not the limiting factor and that patient-centered design guided by stakeholder needs and regulatory requirements would guide their continuous learning digital platform. By digitizing and automating manual repetitive tasks and reducing the logistical burdens on patients and study teams by over 70%, Jeeva accelerates the process of bringing new medicines or vaccines to patients who need them by over 3x faster. The Virginia-based company’s modular software-as-a-service platform is fully scalable and facilitates patient enrollment, engagement, and evidence generation in clinical trials on any browser-enabled mobile device. Visit https://jeevatrials.com/

References: 

1. U.S. Department of Health and Human Services. “Diversity & Inclusion in Clinical Trials.” Updated February 7, 2022, National Institute on Minority Health and Healthy Disparities, nimhd.nih.gov/resources/understanding-health-disparities/diversity-and-inclusion-in-clinical-trials.html.

2. Homedes, Nuria; Ugalde, Antonio. “Globalization and Clinical Research in Latin America.” January 2014, Clinical Trials in Latin America: Where Ethics and Business Clash (pp.55-78), researchgate.net/publication/290735135GlobalizationandClinicalResearchinLatin_America.

Share article on social media or email:

Deploying a Patient-First Framework to Accelerate Recruitment & Reduce Overall Trial Timelines, Upcoming Webinar Hosted by Xtalks


Insider intelligence estimates that 70.6 million US patients, or 26.2% of the population, will use RPM tools by 2025.

The accelerated growth of patient-centric trials is driven by innovations in remote patient monitoring (RPM) and precision medicine. Insider intelligence estimates that 70.6 million US patients, or 26.2% of the population, will use RPM tools by 2025.

With this growth comes new potential, as sponsors and CROs gain the ability to drive better patient outcomes, increase patient adherence, improve health metrics, and ensure seamless patient onboarding.

However, it takes more than simply adding tools to your trial to gain this insight.

Join us on Thursday, November 10, 2022, as experts from Medable’s Digital Medicine and Partner Technologies area showcase: How digital data-flow designs, when mapped with clinical objectives, can support access to wider patient populations improving diversity & inclusion; How to increase operational efficiencies & enhance end-to-end patient enrollment, engagement, and retention; How first-hand experience in dermatology and oncology studies has identified robust patient populations which bring greater benefits to study outcomes; And how the financial value of implementing DCTs can be realized in your organization.

Join Gillian Livock, SVP & GM Digital Endpoints, Medable; Michael Howell, Ph.D., Chief Scientific Officer, DermTech; and Musaddiq (Muz) Khan, VP Therapeutic Area Solutions – Customer Value Team, Medable, for the live webinar on Thursday, November 10, 2022, at 11am EST (4pm GMT/UK).

For more information, or to register for this event, visit Deploying a Patient-First Framework to Accelerate Recruitment & Reduce Overall Trial Timelines.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

University Cancer & Blood Center launches Comprehensive Breast Health Program


University Cancer & Blood Center

“My dream for 30 years has been to take care of my patients with a truly comprehensive approach to breast cancer care.” – Dr. Cody Gunn

University Cancer & Blood Center (UCBC), a leading oncology and hematology practice for Northeast Georgia, is launching its Comprehensive Breast Health Program. It is a customized, personal approach to breast cancer treatment and prevention.

UCBC’s Comprehensive Breast Health Program features a complete staff of highly qualified and dedicated specialists providing state-of-the-art individualized care. This will be a complete and multidisciplinary approach, including surgical care, medical oncology, radiation oncology, and imaging with screening and diagnostic mammogram and ultrasound.

Services include a high-risk screening program that combines advanced technology with expert clinical assessment to determine a woman’s lifetime risk of breast cancer. Features include risk assessment using multiple computerized models to achieve the most accurate results. Women with an elevated lifetime risk of breast cancer may qualify for more intense screening with 3D mammogram and breast MRI as desired. Additional care includes physical examinations, genetic counseling and testing as indicated, and risk-reducing strategies.

“My dream for 30 years has been to take care of my patients with a truly comprehensive approach to breast cancer care,” says expert breast cancer surgeon, Dr. Cody Gunn. “To be able to work alongside UCBC’s medical and radiation oncologists as a part of one team is great for patient care. I believe our comprehensive, personalized care will have a significant positive impact on patient outcomes as well.“

The UCBC Comprehensive Breast Health Program is led by Dr. Gunn and Dr. Ashley Ray, the first fellowship-trained breast surgeon to practice in Athens. Their unique perspectives and backgrounds complement each other in their unified mission to help women prevent, treat, and return to full health after breast cancer treatment. Additionally, the staff specializes in the treatment of benign breast diseases.

The team includes Heather Wheatley, NP, who has long championed the High Risk Breast Clinic, and now Sarah Shanewise, PA, who assists in all facets of breast care. Casey Freeman is a certified nurse navigator who helps guide every woman through all aspects of her breast care.

While the doctors and their team will be seeing patients immediately at UCBC’s North Chase Street location, UCBC is in the process of building a standalone Comprehensive Cancer Center that is scheduled to open summer of 2023. This will be a destination site for all cancer care, including the Comprehensive Breast Health Program.

UCBC Comprehensive Breast Health Program appointments can be made by visiting UniversityCancer.com or by calling (762) 356-4780

Location: UCBC Comprehensive Breast Health Program, 658 N. Chase St., Suite 201, Athens.

Hours: Monday – Friday, 8:00 am to 5:00 pm

About UCBC

University Cancer & Blood Center has been Northeast Georgia’s leading cancer and hematology treatment center for over 40 years. Our highly skilled medical professionals, whose backgrounds include working at the nation’s leading cancer centers, provide every patient with the most advanced cancer care available in an atmosphere of care and compassion. For more information, visit universitycancer.com or call (706) 353-2990.

Share article on social media or email:

Next-Generation Sequencing Applications for Antiviral Drug Development & FDA Guidance for Data Submission, Upcoming Webinar Hosted by Xtalks


Gene variants can compromise virologic response and impact clinical outcomes.

Accurate detection and monitoring of minority variants that confer drug and antiviral resistance is critical to therapeutic and vaccine trials. Specifically, it aids in controlling the emergence of novel variants that can potentially lead to outbreaks of disease and breakthrough infections. Gene variants can compromise virologic response and impact clinical outcomes.

In this webinar the featured speaker explores the following case study:

Eurofins Viracor Biopharma has developed and validated a next-generation sequencing (NGS) assay to determine the genetic variability in the F gene of respiratory syncytial virus (RSV) isolated from human nasal swab (NS) specimens. The NGS method has several advantages over standard Sanger sequencing related to higher sensitivity, quantifiable, cost effective and automatable data analysis steps. The study utilized a deep sequencing approach to quantify minority variants. The patients in this study received a therapeutic targeting RSV. Defined proportions of artificial RNA and virus quasispecies were constructed and their relative proportions were measured using the NGS assay. The assay was validated for the performance characteristics such as analytical sensitivity, precision and accuracy.

To learn more about the applications of this NGS assay and get FDA guidance on data submission, register for this webinar on antiviral drug development.

Join Kirthi Kutumbaka, PhD, Senior Research Scientist, Eurofins Viracor Biopharma, for the live webinar on Friday, November 11, 2022, at 11am EST (4pm GMT/UK).

For more information, or to register for this event, visit Next-Generation Sequencing Applications for Antiviral Drug Development & FDA Guidance for Data Submission.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Kyowa Hakko Announces Glaxon’s Limited-Time Offer Becomes A Permanent Feature


Glaxon permanently adds IMMUSE™ to SuperGreens

Glaxon™, producer of sports nutrition dietary supplements, launched this summer a SuperGreens Enhanced Immune Edition that, in addition to the power of Glaxon™’s trademarked Supershrooms® Organic Mushroom Blend, included IMMUSE™, a postbiotic that provides immune support at a cellular level – both of which support the immune systems of its customers.

“The inclusion of IMMUSE™ was so successful that we decided to soft launch the SuperGreens Enhanced Immune Edition formula in all flavors: Lemon Iced Tea, Orchard Iced Tea, BurstBerry Iced Tea, Dragon Fruit, and the original, limited-time edition offering, Blueberry Açaí,” said Joey Savage, the visionary and formulator of SuperGreens Enhanced Immune Edition.

With a consumer base increasingly interested in immune health, the addition of IMMUSE™ was a logical next step for Glaxon™. Produced by Kyowa Hakko, an international health ingredient and pharmaceutical manufacturer, IMMUSE™ is a thoroughly researched immune activator, with 29 published studies and over ten years of research supporting its mode of action. Specifically, IMMUSE™ is a branded form of the LC-Plasma strain of lactic acid bacteria. These bacteria can activate plasmacytoid dendritic cells (pDCs), which, once triggered, circulate throughout the body mobilizing NK Cells, killer T cells, helper T cells, and B Cells for more comprehensive immune support.

SuperGreens Enhanced Immune Edition is loaded with antioxidants, superfoods, fiber, and enzymes to support the body further. For instance, the Supershrooms® Organic Mushroom Blend is designed to enhance mental focus, athletic support performance and provide beta-glucans to help with healthy white blood cells.*

Karen Todd, MBA, RD, Vice President Global Brand Marketing, Kyowa Hakko USA, Inc., commented, “Glaxon’s decision to include IMMUSE™ in all their SuperGreens formulations is indicative of their product innovation and the increasing consumer demand for effective, science-based immune ingredients.”

Through the addition of IMMUSE™ into the Glaxon™ SuperGreens formulations, Kyowa Hakko is joining a market that is expected to hit USD 11.5 billion by 2030. SuperGreens Immune formulas can be purchased via Glaxon™ or GNC. To learn more about IMMUSE™, go to https://immusehealth.com/.

*The Food and Drug Administration has not evaluated these statements. This product is not intended to diagnose, treat, cure or prevent any disease.

About IMMUSE:

IMMUSE™ is a postbiotic that delivers a new, breakthrough approach to broad range immune support*. As a clinically researched immune activator* supported by 29 published studies, including 14 human trials, IMMUSE™ proactively supports the immune system through a novel method of action that activates pDC (plasmacytoid dendritic cells)*. The pDC, a rare type of immune cell, functions as a key leader of the immune system and has been shown to activate pivotal cells such as NK, Killer-T, Helper-T, and B cells, for a more comprehensive approach to immune support*. Its unique mechanism of action, discovered by Kyowa Hakko’s parent company Kirin Holdings Co., Ltd., is opening doors for discovering postbiotics concerning immune health.

About Kyowa Hakko USA:

Kyowa Hakko USA is the North & South American office of Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing pharmaceuticals, nutraceuticals, and food & beverage products. Kyowa is the maker of branded ingredients, including IMMUSE™ LC-Plasma, Eyemuse™ Lacticaseibacillus paracasei KW3110, Cognizin® Citicoline, Pantesin® Pantethine, Setria® Glutathione, as well as L-Alanyl-L-Glutamine. For more information, visit http://www.kyowa-usa.com.

About GLAXON™:

GLAXON™ is a brand of mold breaking dietary supplements with an emphasis on cross category lifestyle solutions beyond just the active nutrition space. GLAXON™ is one of the fastest growing brands in the space that has become an emerging leader in market innovation. Leveraging growth by disruptive thought-provoking branding, product education, and transparent supplements that provide lifestyle solutions. GLAXON™ is headquartered in a 100,000 sq ft facility of product incubation including: design, formulation, manufacturing, marketing, and sales. GLAXON™ headquarters is uniquely built to fast-track product concepts from R&D to fully finished products all under one roof remaining true to the company mantra, “Made with Real Science”. GLAXON™ can be found at GNC, GLAXON.com, and select retailers globally. For more information visit GLAXON.com or find us on Instagram and TikTok.

Share article on social media or email:

Veterans Count Nashua’s In-person Salute Our Soldiers Gala Returns


Easterseals NH Veterans Count Nashua Chapter Salute Our Soldiers Gala.

Eric Schindler, NH State Director of Bugles Across America, plays Taps during the 2021 Easterseals Veterans Count Salute Our Soldiers event.

“Military service members and their families sacrifice so much for our collective freedom. This Salute Our Soldiers Gala serves to return that care to both enlisted service members and veterans statewide,” says Maureen Beauregard, President and CEO, Easterseals NH, VT & Farnum.

After two years of virtual events, the Easterseals Nashua, New Hampshire Chapter of Veterans Count is pleased to announce it will host its 11th annual Salute Our Soldiers Gala in-person on Saturday, November 12 at 5 pm, at Sky Meadow Country Club in Nashua. The event will honor the contributions of women in the military over the past century.

The Gala will feature a cocktail reception and surf and turf dinner and Sy Mahfuz, founder of PRG Rugs in Nashua, will serve as emcee. Catherine Smart, a policy analyst with Applied Research Associates and veteran of the United States Army Military Police, will deliver the keynote address, and nationally recognized singer and impressionist Tony Pace will provide entertainment. The winner of the 2022 Founders Award will be unveiled during the program.

Easterseals NH Veterans Count directly addresses issues affecting the military community, including suicide risk and mental health, unemployment, homelessness, substance use, and legal concerns. Veterans Count provides emergency financial assistance for food, utilities, housing, transportation, fuel, and vehicle repair. All proceeds from the Salute Our Soldiers Gala will benefit this work.

“The Easterseals Veterans Count team is excited to gather in-person once again to recognize the essential contributions of women in the United States military across all branches, while raising critical funds for our services,” says Maureen Beauregard, President and CEO, Easterseals NH, VT & Farnum. “Military service members and their families sacrifice so much for our collective freedom. This Salute Our Soldiers Gala serves to return that care to both enlisted service members and veterans statewide.”

For more information and to purchase tickets, visit https://vetscount.org/nh/events/nashua-salute-our-soldiers-gala/. To learn more about event sponsorship opportunities, contact Katherine Richard at (603) 621-3456.

ABOUT VETERANS COUNT

Easterseals New Hampshire’s Veterans Count was founded in 2007 to provide case management and emergency financial assistance to meet the unexpected needs of service members, veterans, and their families. Veterans Count provides critical and timely financial assistance and services when no other resource is available. Emergency financial assistance may include rental assistance, gas, food, or utility payments. Last year alone, the program served more than 1,660 veterans, assisting them in accessing eligible benefits and services, housing, counseling services, and other needs, including emergency financial assistance to build a sustainable, secure, and viable future. Our commitment is to ensure the dignity, health, and overall well-being of each service member, veteran, and their families. For more information, visit https://vetscount.org/nh/.

ABOUT EASTERSEALS NEW HAMPSHIRE

For more than 84 years, Easterseals New Hampshire has provided exceptional services to ensure that all people of all ages with varied abilities and their families have equal opportunities to live, learn, work, and play in their communities. As a leader in social services for individuals with disabilities and other challenges, Easterseals NH employs more than 1,600 individuals and provides essential services and on-the-ground supports to more than 23,000 people each year with 11 core programs throughout the state. Visit https://www.easterseals.com/nh/.

Share article on social media or email:

CareAparent Wins Gold Best In-Home Care and Bronze Best Physical Therapy Star Tribune Readers’ Choice Minnesota Best Awards for 2022


“…As a home health provider our core values are excellence, trust, compassion, collaboration, and safety. Receiving this honor affirms that we are living out those values and improving the lives of the clients we serve every day.” – Dominic Todora, President, CareAparent.

CareAparent, a premier provider of Home Health and Personal Cares in Minnesota for seniors living independently at home, is pleased to announce receiving the gold medal for Best In-Home Care and the bronze medal for Best In-Home Physical Therapy in Star Tribune Readers’ Choice Minnesota Best Awards for 2022.

“CareAparent is honored to be recognized by our clients and the public for the services and in-home care we provide. As a home health provider our core values are excellence, trust, compassion, collaboration, and safety. Receiving this honor affirms that we are living out those values and improving the lives of the clients we serve every day.” – Dominic Todora, President, CareAparent.

“Being recognized by Minnesota’s Best echoes the dedication our teams have for our clients. We are committed to providing quality care and our focus is, and will continue to be, excellence.” – Jose Colon, CareAparent Therapy Manager.

CareAparent is a trusted provider of home health and personal care services, including skilled nursing care, occupational therapy, physical therapy, personal care and hospice support. Accredited by the Joint Commission and certified under Medicare and Medicaid, CareAparent offers essential in-home care services throughout the Twin Cities, including veterans, whenever it’s needed, allowing our clients to continue enjoying life in a familiar, and comfortable environment. Passionate and experienced teams are available 24-hours a day and every day of the week, including weekends and holidays.

To learn more about CareAparent or schedule a complimentary consultation, please visit CareAparent.com.

Share article on social media or email: